Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis
Nerea Mora Ayestarán(Hospital Universitario Puerta de Hierro Majadahonda), Pritam Gupta(Pfizer (India)), Igor Diemberger, Oliver Glass(Pfizer (United States)), Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Pablo García‐Pavía(Universidad Francisco de Vitoria), Arnt V. Kristen(Heidelberg University), Brian Drachman(Penn Presbyterian Medical Center), Martha Grogan(Mayo Clinic in Arizona), Angela Dispenzieri(Mayo Clinic), Leslie Amass(Pfizer (United States))
Cited by 18
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k